PDS Biotechnology Corp. (PDSB)
1.09
-0.07
(-6.03%)
USD |
NASDAQ |
Oct 23, 12:49
PDS Biotechnology Net Income (Quarterly) : -9.751M for June 30, 2026
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -9.751M |
| March 31, 2026 | -7.349M |
| December 31, 2025 | -7.563M |
| September 30, 2025 | -9.009M |
| June 30, 2025 | -9.434M |
| March 31, 2025 | -8.489M |
| December 31, 2024 | -7.952M |
| September 30, 2024 | -10.73M |
| June 30, 2024 | -8.328M |
| March 31, 2024 | -10.60M |
| December 31, 2023 | -10.90M |
| September 30, 2023 | -10.85M |
| June 30, 2023 | -11.53M |
| March 31, 2023 | -9.660M |
| December 31, 2022 | -19.14M |
| September 30, 2022 | -7.424M |
| June 30, 2022 | -5.819M |
| March 31, 2022 | -8.474M |
| December 31, 2021 | -6.32M |
| September 30, 2021 | -6.961M |
| June 30, 2021 | -0.5889M |
| March 31, 2021 | -3.049M |
| December 31, 2020 | -4.027M |
| September 30, 2020 | -3.906M |
| June 30, 2020 | -2.929M |
| Date | Value |
|---|---|
| March 31, 2020 | -3.985M |
| December 31, 2019 | -4.178M |
| September 30, 2019 | -5.752M |
| June 30, 2019 | -3.886M |
| March 31, 2019 | 6.817M |
| December 31, 2018 | -1.820M |
| September 30, 2018 | -0.7112M |
| June 30, 2018 | -0.5678M |
| March 31, 2018 | -0.7379M |
| December 31, 2017 | -13.90M |
| September 30, 2017 | -11.28M |
| June 30, 2017 | -13.50M |
| March 31, 2017 | -12.17M |
| December 31, 2016 | -9.515M |
| September 30, 2016 | -10.76M |
| June 30, 2016 | -9.376M |
| March 31, 2016 | -9.170M |
| December 31, 2015 | -7.959M |
| September 30, 2015 | -10.13M |
| June 30, 2015 | -5.521M |
| March 31, 2015 | -4.468M |
| December 31, 2014 | -3.163M |
| September 30, 2014 | -3.518M |
| June 30, 2014 | -3.008M |
| March 31, 2014 | -2.513M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| ACADIA Pharmaceuticals, Inc. | 31.50M |
| Alnylam Pharmaceuticals, Inc. | 164.49M |
| Anika Therapeutics, Inc. | 3.309M |
| Savara, Inc. | -40.23M |
| Vericel Corp. | 2.206M |
Net Income (Quarterly) Related Metrics
| Total Expenses (Quarterly) | 9.751M |
| EPS Diluted (Quarterly) | -0.1752 |
| Enterprise Value | 63.64M |
| Earnings Yield | -58.74% |
| Normalized Earnings Yield | -58.74 |